Protalix BioTherapeutics, Inc. financial data

Symbol
PLX on NYSE
Location
2 University Plaza, Suite 100, Hackensack, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 238 % +62.6%
Quick Ratio 80.5 % +94%
Debt-to-equity 68.3 % -60.2%
Return On Equity 14.7 %
Return On Assets 8.73 %
Operating Margin 13.3 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 79.7M shares +8.42%
Common Stock, Shares, Outstanding 75.9M shares +3.97%
Entity Public Float 82M USD -41.1%
Common Stock, Value, Issued 76K USD +4.11%
Weighted Average Number of Shares Outstanding, Basic 78.7M shares +7.31%
Weighted Average Number of Shares Outstanding, Diluted 81.3M shares +10.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 61.9M USD +62.8%
Cost of Revenue 26.3M USD +1.95%
Research and Development Expense 16.6M USD +31.5%
Operating Income (Loss) 8.23M USD
Nonoperating Income (Expense) -139K USD +61.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 8.09M USD
Income Tax Expense (Benefit) 1.81M USD
Net Income (Loss) Attributable to Parent 6.28M USD
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.9M USD -23.5%
Accounts Receivable, after Allowance for Credit Loss, Current 9.44M USD -6.75%
Inventory, Net 21.1M USD +1.99%
Other Assets, Current 1.51M USD +1.34%
Assets, Current 65.5M USD -15.4%
Deferred Income Tax Assets, Net 2.74M USD -17%
Property, Plant and Equipment, Net 4.75M USD +2.97%
Operating Lease, Right-of-Use Asset 5M USD -12.8%
Assets 78.5M USD -14.3%
Accounts Payable, Current 19.6M USD +4.47%
Employee-related Liabilities, Current 1.53M USD +26.7%
Accrued Liabilities, Current 7.31M USD -22.1%
Contract with Customer, Liability, Current 12.7M USD
Liabilities, Current 24.1M USD -58.4%
Operating Lease, Liability, Noncurrent 3.88M USD -9.46%
Liabilities 28.6M USD -54.6%
Retained Earnings (Accumulated Deficit) -378M USD +0.83%
Stockholders' Equity Attributable to Parent 49.9M USD +74.6%
Liabilities and Equity 78.5M USD -14.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.06M USD -221%
Net Cash Provided by (Used in) Financing Activities 5.08M USD
Net Cash Provided by (Used in) Investing Activities -312K USD +48.5%
Common Stock, Shares Authorized 185M shares 0%
Common Stock, Shares, Issued 75.9M shares +3.97%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -302K USD -108%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 17.9M USD -23.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 766K USD -28.9%
Deferred Tax Assets, Valuation Allowance 50.7M USD -1.85%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Operating Lease, Liability 5.53M USD -8.36%
Depreciation 346K USD +7.45%
Payments to Acquire Property, Plant, and Equipment 306K USD -48.8%
Lessee, Operating Lease, Liability, to be Paid 7.87M USD -12.9%
Property, Plant and Equipment, Gross 40.3M USD +1.69%
Operating Lease, Liability, Current 1.47M USD +1.52%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.24M USD -11.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.5M USD +6.46%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Deferred Income Tax Expense (Benefit) 561K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.34M USD -22%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.09M USD -3.56%
Deferred Tax Assets, Operating Loss Carryforwards 50M USD -2.83%
Current Income Tax Expense (Benefit) 266K USD
Preferred Stock, Shares Authorized 100M shares
Unrecognized Tax Benefits 805K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.04M USD -0.38%
Deferred Tax Assets, Net of Valuation Allowance 2.86M USD -7.63%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares